Brunetta Denise Menezes, Vlachodimitropoulou Evangelia, Prasannan Nita, Seed Paul T, Oteng-Ntim Eugene
Division of Women's Health Kings College London St Thomas' Hospital London UK.
Empresa Brasileira de Servicos Hospitalares - EBSERH Fortaleza Brazil.
EJHaem. 2025 Apr 24;6(2):e21086. doi: 10.1002/jha2.1086. eCollection 2025 Apr.
Sickle cell disease (SCD) poses significant risks during pregnancy. Transfusions are the only recommended treatment, but there is no strong evidence of its efficacy. The aim of this study was to evaluate prophylactic transfusion on pregnancy outcomes.
We performed a systematic review and meta-analysis (PROSPERO-CRD42024510511), using MEDLINE, EMBASE, Cochrane, Web of Science, and Maternity and Infant Care. No date or language restrictions were applied. Inclusion criteria comprised randomised-controlled trials (RCTs) involving SCD pregnancy, comparing maternal and foetal outcomes for prophylactic versus on-demand transfusions. Two independent reviewers performed screening, selection, and data extraction, following PRISMA. Two authors independently assessed certainty and risk-of-bias. Data were pooled using random-effects model. Primary outcomes included mortality, vaso-occlusive crisis (VOC), acute chest syndrome, venous thromboembolism and preterm delivery. The measure of the effect was the unadjusted odds ratio (OR), calculated from numbers of events.
Ninety-one studies were identified and two RCTs (106 patients) were included, with uncertain and low risk of bias. Prophylactic transfusions reduced VOC, OR of 0.197 (95% CI 0.08-0.49). However, due to the small number of patients, this meta-analysis was underpowered to evaluate other outcomes.
A larger RCT is needed to comprehensively assess the impact of prophylactic transfusion in SCD pregnancy.
镰状细胞病(SCD)在孕期会带来重大风险。输血是唯一推荐的治疗方法,但尚无有力证据证明其疗效。本研究旨在评估预防性输血对妊娠结局的影响。
我们进行了一项系统评价和荟萃分析(PROSPERO-CRD42024510511),使用了MEDLINE、EMBASE、Cochrane、科学网和母婴护理数据库。未设置日期或语言限制。纳入标准包括涉及SCD妊娠的随机对照试验(RCT),比较预防性输血与按需输血的母婴结局。两名独立审阅者按照PRISMA进行筛选、选择和数据提取。两名作者独立评估确定性和偏倚风险。使用随机效应模型汇总数据。主要结局包括死亡率、血管闭塞性危象(VOC)、急性胸部综合征、静脉血栓栓塞和早产。效应量的衡量指标是根据事件数量计算的未调整优势比(OR)。
共确定了91项研究,纳入了两项RCT(106例患者),偏倚风险不确定且较低。预防性输血降低了VOC,OR为0.197(95%CI 0.08 - 0.49)。然而,由于患者数量较少,该荟萃分析评估其他结局的能力不足。
需要进行更大规模的RCT来全面评估预防性输血对SCD妊娠的影响。